GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik's team at Asan Medical Center has been published in The American Journal of Gastroenterology(AJG).
https://mma.prnewswire.com/media/2833373/GC_Genome_logo_final_Logo.jpg
GC Genome applied its proprietary AI-based fragmentomics technology, used in its MCED test, ai-CANCERCH. This study demonstrates the potential for a convenient, alternative to colonoscopy and fecal based screening methods, while enabling early detection of colorectal cancer and advanced adenomas.
Study Overview
— A total of 1,677 individuals were enrolled, including: 302 withCRC, 108 with AA
— 1,267 with normalcolonoscopy as healthy or non-cancer controls
The test analyzes cfDNA fragmentomic signatures using low-coverage whole-genome sequencing (Lc-WGS) combined with a proprietary AI algorithm, enabling highly sensitive detection of early-stage disease.
Key Findings
— CRC sensitivity: 90.4%
— Specificity in individuals with normalcolonoscopy: 94.7%
— Sensitivities byCRC stage : 84.2% (stage I), 85.0% (stage II), 94.4% (stage III), and 100.0% (stage IV)
— Sensitivity for T1N0 lesions (eligible forendoscopic resection): 90.0%
— Sensitivity for AA: 58.3%
The results remained consistent regardless of: CRC locations (left vs. right colon), age of CRC patients(<60 vs. ≥60), and AA locations
These findings highlight the test's potential as a reliable cfDNA-based blood test for CRC screening and early prevention.
A GC Genome spokes person stated “Detecting colorectal cancer together with precancerous lesions represents a meaningful advance in prevention. With our fragmentomics technology now validated through publication in a leading gastroenterology journal, GC Genome will continue expanding global clinical collaborations and screening applications.”
About ai-CANCERCH
Launched in September 2023, ai-CANCERCH is an AI-based multi-cancer early detection(MCED) test powered by Lc-WGS. Using just 10 mL of blood, the test detects signals associated with multiple cancers. A major upgrade-expanding from 6 detectable cancers to 10 cancers (colorectal, lung, esophageal, liver, ovarian, pancreatic, biliary, breast, gastric, and head-and-neck)-is planned for January 2026.
About GC Genome
GC Genome is a leading diagnostics company that aims to connect the care and cure to the world by offering genetic diagnosis services for Oncology, Pre&Neonatal, Rare Diseases, and Health Check-ups and suggesting personalized treatment for longer and healthier lives. Established in 2013 as a GC company, GC Genome operates a CAP-accredited laboratory and places the utmost emphasis on R&D. With steadfast partnerships established worldwide, GC Genome has shown impressive growth momentum, continually expanding our testing capacities.
GC Genome Contacts (Media)
Sohee Kimshkim20@gccorp.com
Yelin Junyelin@gccorp.com
Yoonjae Nayjy6520@gccorp.com
https://edge.prnewswire.com/c/img/favicon.png?sn=CN34458&sd=2025-11-27
View original content to download multimedia:https://www.prnewswire.com/news-releases/gc-genome-publishes-blood-based-colorectal-cancer-screening-study-in-the-american-journal-of-gastroenterology-302627272.html
SOURCE GC Genome
https://rt.newswire.ca/rt.gif?NewsItemId=CN34458&Transmission_Id=202511270000PR_NEWS_USPR_____CN34458&DateId=20251127